| 摘要 |
Kv1.5 potassium channel inhibitors (I) are used to prepare medicaments for treating or preventing breathing disorders, including sleep-related breathing disorders, central and obstructive sleep apnea, Cheyne-Stokes breathing, snoring, impaired central respiration, cot death, postoperative hypoxia and apnea, muscle-related breathing disorders, breathing disorders after long-term artificial respiration, breathing disorders associated with altitude acclimatization and lung diseases with hypoxia and hypercapnia; neurodegenerative diseases, including dementia, Alzheimer's disease, Parkinson's disease and Huntington's disease; and cancer, including breast, lung, colon and prostate cancer. ACTIVITY : Neuroprotective; Nootropic; Antiparkinsonian; Anticonvulsant; Cytostatic. MECHANISM OF ACTION : Kv1.5 potassium channel inhibitor; TASK potassium channel inhibitor. 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide had an IC50 of 0.1 mu M for blockade of human TASK-1 channels. |
